A major pharmaceutical province, began to prepare for non-evaluated drug tape procurement!

Recently, "Anhui Province public medical institutions clinical commonly used drug centralized drug procurement negotiation bargaining implementation plan (draft for comments)" in the industry, according to the contents of the document shows that Anhui Province will further improve the non-over-evaluation of drug centralized drug procurement negotiation bargaining mechanism, promote the normalization of the volume of procurement, reduce the price of drug procurementthat is, Anhui Province will be commonly used clinical non-over-rated drugs for the volume of procurement price negotiations, and in accordance with the total annual use of 70% of the total purchase volumein fact, in addition to Anhui, this year, many places have appeared for the drug has not been evaluated for the volume of procurement notice, as on January 13, Fujian Provincial Medical Security Bureau, provincial health committee and provincial drug regulatory bureau jointly issued the "Notice on expanding the scope of drug collection and purchase", Fujian will soon be the outstanding varieties of belt procurementAccording to the notice, the scope of expanding centralized procurement of drugs mainly includes: some of the purchase amount is large, full competition, clinical use is mature, the same generic name has not yet had generic drugs through quality and efficacy consistency evaluation of drugs, by the Fujian Provincial Health Insurance Bureau, health care commission, the Drug Administration jointly organized experts to carry out centralized procurementIn addition to, Fujian Province will also be in accordance with the province's public medical institutions in the same general name last year did not pass the quality and efficacy consistency evaluation of the total amount of generic drugs estimated the procurement base of 70%, to ensure that the procurement cycle to complete the basic amount, the use of selected drugs in principle not less than 60% of the total use of generic generic drugs, to carry out tape procurement, volume-for-priceOn April 18,, Sanming Alliance also announced the results of eight non-consistent evaluation drug band procurement quotationsaccording to the collection requirements, the low price is the proposed drugs, the lower price is an alternative, and do not do bad price calculation of dosage form, packaging, package materialthere are two sets of results to be selected and selectedin fact, although the procurement of unrated drugs has been a regular occurrence, but in recent years has not been evaluated varieties throughout the country in a significant situationfrom Anhui Province this document content can be seen, it will also reduce drug prices as the main goal of this volume procurement, the unrated varieties have made a hanging online price must not be higher than the price limit of the over-rated varietiesindustry insiders pointed out that, in view of the current evaluation of varieties is still a small number of transition period, Anhui and other provinces and cities can also understand the move, but for the evaluation of generic drug enterprises whether good still need to be observedin accordance with the recent form of collection, whether it is the use of centralized bidding or negotiations, price reduction is an essential measure for pharmaceutical companies, the difference is only in the price reductionin general, carrying out generic drug consistency evaluation, can make generic drugs in terms of quality and efficacy consistent with the original research drug, clinically can replace the original research drug, which can not only save medical costs, but also improve the quality of generic drugs in China and the overall level of development of the pharmaceutical industry, to ensure the safety and effectiveness of public drug use , therefore, in the "three" has become a large number of generic approvals have been suspended on the network of important critical point, for the vast number of generic drug companies, it is necessary to enhance the production capacity of pharmaceutical companies themselves, continue to accelerate the adoption of consistency evaluation .